SSG XVIII/AIO: one versus three years of adjuvant imatinib for operable gastrointestinal stromal tumour
Three years of imatinib after surgery for high-risk gastrointestinal stromal tumour reduced recurrences and deaths compared with one year, setting the standard duration of adjuvant therapy.
Overview
Phase 3 trial of 400 patients with resected KIT-positive GIST at high risk of recurrence randomised to 12 or 36 months of adjuvant imatinib 400 mg daily.
Five-year recurrence-free survival was 65.6 versus 47.9 percent (hazard ratio 0.46) and five-year overall survival 92.0 versus 81.7 percent (hazard ratio 0.45); ten-year follow-up confirmed the survival benefit, and discontinuation for adverse events was more common with longer treatment.
- Five-year recurrence-free survival 65.6 percent vs 47.9 percent; hazard ratio 0.46.
- Five-year overall survival 92.0 percent vs 81.7 percent; hazard ratio 0.45.
Three years of adjuvant imatinib is standard for high-risk resected GIST with imatinib-sensitive mutations; longer courses are being tested.
- Patients with PDGFRA D842V mutations, which are imatinib-resistant, do not benefit.
- Recurrences resume after imatinib is stopped.
Similar pages
not linked directly; found by shared links- Key paperEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours
Shares KIT exon 11-mutant GIST, Imatinib.
- Key paperKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour
Shares KIT exon 11-mutant GIST, Imatinib.
- TermGIST risk stratification (mitotic count, size, site; Miettinen and modified NIH criteria)
Shares KIT exon 11-mutant GIST, Imatinib.